Advisors Give Lukewarm Endorsement Of St. Jude's PFO Occluder For Stroke
This article was originally published in Clinica
Executive Summary
FDA advisors agreed with St. Jude Medical that its Amplatzer patent foreman ovale occluder has benefits for select patients that outweigh the risks for recurrent strokes, at a Circulatory System Devices Panel meeting.
You may also be interested in...
Positive Long-Term Data Plug Doubts Over PFO-Closure Stroke Benefits
Data from the REDUCE, CLOSE, and RESPECT trials, published in the New England Journal of Medicine, showed that closing a patent foramen ovale with a percutaneous closure device can reduce the risk of ischemic stroke in patients who have already had a cryptogenic stroke. Observers believe these trials showed a benefit of PFO closure in this population after previous trials failed to show a benefit largely because they did a better job of only selecting patients most likely to benefit.
US Approvals Analysis: Stroke Device, IVDs Highlight October FDA Actions
A PFO-closure device was finally approved for stroke in October. Also during the month, important personalized medicine diagnostics approvals and a next-gen robotic system for stent procedures.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”